#temcel | Explore Tumblr posts and blogs

deepadelve · 3 years ago

Text

Graft Versus Host Disease Market

Graft versus host disease (GvHD) is a disease caused when cells from a donated stem cell graft attack the normal tissues of the transplant patient. Symptoms include jaundice, skin rash or blisters, a dry mouth, or dry eyes. GVHD occurs when a particular types of white blood cells (T cells) in the donated bone marrow or stem cells attack the host body cells because the donated cells (the graft) see the host cells as foreign and attack them.

DelveInsight's "Graft versus host disease (GVHD) Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Graft versus host disease (GVHD), historical and forecasted epidemiology as well as the Graft versus host disease (GVHD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some facts of the Graft versus host disease Market report:

The GvHD market size in the 7MM is expected to change during the study period 2018–2030, at a CAGR of 15.9%.

In 2020, the 7MM reported 24,049 allogeneic cases, with a CAGR projecting increase in cases by 2030. The United States accounted for 9,857 allogeneic cases in 2020, representing the highest percentage, of all allo-HSCT in the 7MM.

GvHD is categorized into two types: aGvHD and cGvHD.

In 2020, acute GvHD cases accounted for 11,638, while chronic cases accounted for 7,854. In the 7MM, the aGvHD and cGvHD cases are expected to rise to by 2030 during the forecast period, i.e., 2021–2030.

Germany has the highest number of cases of GvHD by type (acute and chronic) among the EU-5 nations, with 2,984 in 2020.

In the event of GvHD, corticosteroids are the first line of treatment; however, secondary data demonstrate that up to 40%-60% of all patients will be refractory to steroids. As per DelveInsight’s analysis, around 3,278 cases of cGvHD treated in first-line in the United States in 2020

The mortality-adjusted treatment rate is used to estimate the number of living patients who are receiving treatment or who will be eligible for treatment. In 2020, the 7MM mortality adjusted treated aGvHD patients were 9,951 in first-line.

The key players in GvHD market are:

Imbruvica

Temcell HS

Incyte Corporation

Enlivex Therapeutics

Kiadis Pharma

OncoImmune

And Many Others

GvHD has two types Acute GvHD and Chronic GvHD. Acute GvHD is also known as fulminant GVHD, and occurs usually in the initial 2-3 months after transplantation. While Chronic GVHD occurs around 3-4 months after the transplantation has happened, and has more diverse complications. This type affects liver, stomach, vagina, joints, lungs, gut, mouth and glands secreting mucous or saliva.

Acute GVHD is staged and graded (grade I-IV) by the number and extent of organ involvement. While Chronic GvHD is staged according to a new clinical scoring system on a four point scale (0-3) with 0 representing no involvement, 1 representing mild involvement (no significant impairment of daily living), 2 representing moderate involvement (significant impairment of daily living) and 3 representing severe impairment (major disability).

“According to Delveinsight, No significant difference was found in incidence of GvHD among male and female”

The launch of the emerging therapies is expected to significantly impact Graft versus host disease (GvHD) treatment scenario in the upcoming years:-

Graft versus host disease therapies covered:

Imbruvica

Temcell HS

Ruxolitinib

Itacitinib

Allocetra

ATIR101

CD24Fc

And Many Others

Table of contents:

Key Insight

Executive Summary of Graft Versus Host Disease (GvHD)

Graft Versus Host Disease (GvHD) Market Overview at a Glance

Disease Background and Overview: Graft Versus Host Disease (GvHD)

Case Reports

Graft Versus Host Disease (GvHD) Epidemiology and Patient Population

United States Epidemiology

EU5 Epidemiology

Japan Epidemiology

Current Graft Versus Host Disease (GvHD) Treatment and Medical Practices

Unmet needs

Graft Versus Host Disease (GvHD) Marketed Drugs

Graft Versus Host Disease (GvHD) Emerging Drugs

Graft Versus Host Disease (GvHD) 7MM Market Analysis

United States

EU-5 countries: Market Outlook

Japan Market Outlook

Graft Versus Host Disease (GvHD) Market Drivers

Graft Versus Host Disease (GvHD) Market Barriers

SWOT Analysis

Reimbursement and market access

Appendix

DelveInsight Capabilities

Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

0 notes

pharmaphorumuk · 6 years ago

Text

Mesoblast poised to file cell therapy for GVHD in US

Australian biotech Mesoblast can go ahead with a US filing for its off-the-shelf stem cell therapy for acute graft-versus-host disease (GVHD), after negotiations with the FDA.

The ‘rolling’ biologics license application (BLA) for remestemcel-L in children with steroid-refractory acute GVHD – a life-threatening complication that can arise in blood cancer patients who’ve had bone marrow transplants – comes a few months after the company revealed positive trial data with the therapy.

In the 55-patient open-label trial study reported last year, 69% of treated children had a complete or partial response, which compares to a historical control response rate of around 45%.

GVHD is one of the leading causes of death in patients receiving donor stem cell transplants, and occurs when the donated bone marrow cells mount an immune response against the recipient’s healthy tissues.

Steroids are the first-line therapy, but in around 15% of cases can’t resolve the acute inflammatory response. In those cases, the death rate can be as high as 70% after 100 days, but in Mesoblast’s trial 78% of patients treated with remestemcel-L were still alive at that timepoint.

Mesoblast said it will submit each module of the BLA to the FDA on a rolling basis as it is completed. That approach will provide “opportunity for ongoing and frequent communication, and during this process the company expects it will be able to adequately address any substantial matters raised by the FDA”, said the company in a statement.

Remestemcel-L has already been granted a fast track designation from the FDA and will be eligible for priority review once the filing is accepted by the FDA.

The therapy has already been approved for GVHD in Japan, where it is sold by licensee JCR Pharmaceuticals as Temcell HS Inj, and was filed last month for the additional indication of epidermolysis bullosa, a serious rare genetic disease in which minor friction causes blisters or erosion of the skin.

News of a filing is a boost to Mesoblast, after its Revascor (MPC-150-IM) therapy failed to hit the mark in a phase 2 trial in heart failure patients reported last November.

Injections of MPC-150-IM (mesenchymal precursor cells) directly into the myocardium during the implantation of a left ventricular assist device (LVAD) did not improved the chances of them being able to do without the device, although the therapy did work in some subgroups.

The biotech is planning a second trial that will try to show that the therapy can reduce complications including gastrointestinal bleeding in end-stage heart failure patients implanted with an LVAD.

The therapy is still in a larger phase 3 trial pf Revascor in chronic heart failure that completed patient recruitment earlier this year. Former partner Teva returned the rights to the therapy in 2016.

The post Mesoblast poised to file cell therapy for GVHD in US appeared first on Pharmaphorum.

from Pharmaphorum https://pharmaphorum.com/news/mesoblast-cell-therapy-gvhd-fda/

0 notes

saojip13 · 5 years ago

Text

Stem Cell Therapy Market Players: Cytori Therapeutics Inc., Fibrocell Science, Cellartis AB, BioTime, GE Healthcare, etc

Stem cell therapy involves use of stem cells to treat various diseases or disorders. Stem cells are fundamental for every tissue and organ in the body. Stem cells are indistinguishable biological cells that are able to differentiate into specialised cells (liver cells, cardiac cells etc.) and can renew itself (through mitosis) to produce more stem cells. Stem cells have the ability to replicate, repair, and replace other damaged tissues in the human body. In addition, stem cell based therapies are also used to treat several chronic diseases such as blood disorders, cancer and others.

Get a Sample Copy of this Report @ https://www.alexareports.com/report-sample/170621

Growing awareness about the potency of stem cells in disease management, development of advanced gene based analysis techniques and increase in public, private investments in stem cell research are acting as growth drivers for stem cell therapy market. In addition, identification of new stem cell lines and development of infrastructure for stem cell banking & processing are propelling the growth of the global stem cell therapy market. However, ethical issues involved in stem cells research such as destruction of human embryos, religious beliefs are considered as road blocks for adaptation of stem cell therapy by patients. However, stringent regulations to conduct trials on humans, high-cost of research and storage of stem cells are some restraining factors for stem cell therapy market.

Stem cell therapy market has been segmented on the basis of treatment mode, cell types, application, technology, and end-user

Based on treatment, stem cell therapy market is segmented into

Allogeneic Autologous

Based on cell type, stem cell therapy market is segmented into

Adult Stem cells Induced Pluripotent Stem cells Human Embryonic Stem Cells Others

Based on technology, stem cell therapy market is segmented into

Cell Production Cell Acquisition Cryopreservation

Based on end-user, stem cell therapy market segmented into

Hospitals Ambulatory Centers Research Centers

Grab amazing discount here @ https://www.alexareports.com/check-discount/170621

Stakeholders in stem cell therapy such as academic institutions and research firms are collaborating in development of stem cell therapy and industry collaborations also projecting enormous growth of stem cell therapy market. For instance, in November 2015, Cellular Dynamics International, Inc. (FUJIFILM) collaborated with Roche to supply iCell (CDI’s induced pluripotent stem cell derived) products that enables in identification of novel drug candidates at the early stages of drug discovery. Similarly, in May 2018, Magenta Therapeutics, entered into strategic partnership with Be The Match BioTherapies, to improve and expand the use of curative stem cell transplantation.

Geographically stem cell therapy market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Among the regions, North America dominates global stem cell therapy market due to factors such as increasing prevalence of chronic diseases, growing awareness, and rising investment in research and development activities. In Asia Pacific region, due to the favourable government policies, development healthcare infrastructure, industry collaborations in research and developments expected to boost stem cell therapy market. For instance, in April 2018, Plasticell, a developer of stem cell technologies and cell-based therapies, has announced that it has signed agreements with the Agency for Science, Technology and Research (A*STAR), Singapore, and the Nanyang Technological University (NTU), Singapore, to progress its therapeutic stem cell pipeline.

Some of the players in stem cell therapy market are Cytori Therapeutics Inc. (U.S.), Fibrocell Science (U.S.), Cellartis AB (Cellectis) (France), BioTime, Inc. (U.S.), GE Healthcare (U.S.), Thermo Fisher Scientific (U.S.), STEMCELL Technologies Inc. (Canada), Fujifilm Holdings Corporation (Japan), Vericel Corporation (Aastrom Bioscience) (U.S.), Brainstorm cell therapeutics (U.S.), Becton, Dickinson and Company (U.S.), Stryker Corporation (U.S.), Celgene Corporation (U.S.), and Osiris Therapeutics, Inc. (U.S.) to name a few.

To Enquire About This Comprehensive Report@ https://www.alexareports.com/send-an-enquiry/170621

In February 2016, Mesoblast Limited’s licensee in Japan, JCR Pharmaceuticals Co. Ltd., launched “TEMCELL HS Inj”, the first allogeneic cell therapy to be fully approved in Japan, for the treatment of acute graft versus host disease in children and adults

Details of the market study:

Historical Data: 2014 & 2017

Base Year: 2018

Forecasts: 2019-2025

CAGR: 2019-2025

Market trend analysis in terms of drivers, restraints and opportunities

Industry analysis using Porter’s, PESTEL and SWOT

Market players analysis in terms of company’s overview, financial performance, product/service benchmarking and strategic initiatives taken up by them

#Stem Cell Therapy Market

0 notes